Clozapine, one of the most effective treatments for treatment-resistant schizophrenia, has long carried a difficult metabolic trade-off. The medicine can reduce psychotic symptoms when other antipsychotics fail, yet it is also associated with weight gain, insulin resistance and changes in blood lipids. A new study published in Translational Psychiatry draws attention to a less visible biological event that may help explain one of these complications: structural changes in the tiny blood vessels of the liver.
The research, led by T. Voloshyna, Ø.V. Svendsen and K. Szafranska and published in 2026, examines the association between clozapine-induced hypertriglyceridemia and the “defenestration” of liver sinusoidal endothelial cells. Hypertriglyceridemia refers to an abnormal elevation of triglycerides, the main form of fat transported in the bloodstream. Although triglycerides are essential for energy storage and metabolism, persistently high concentrations are linked to inflammation, cardiovascular disease and, in severe cases, pancreatitis.
The liver is central to controlling these circulating fats. Blood arriving from the digestive system and other organs passes through specialized channels called hepatic sinusoids before leaving through the liver’s venous network. The walls of these channels are lined by liver sinusoidal endothelial cells, or LSECs. Unlike the endothelial cells lining most ordinary blood vessels, LSECs contain thousands of microscopic openings known as fenestrae. These pores help regulate the movement of lipoproteins, nutrients and other molecules between the bloodstream and liver cells.
The term “defenestration” describes the loss, reduction or closure of these openings. When LSECs become defenestrated, the normally porous barrier becomes less permeable. That transformation is important because the architecture of the sinusoidal wall determines how efficiently particles in the blood can reach hepatocytes, the liver’s primary working cells. Changes in this exchange system may influence how the liver processes lipids, although the precise direction and biological consequences can depend on the disease context.
The study focuses on whether this cellular remodeling is connected to the rise in triglycerides observed during clozapine treatment. Its central contribution is to place a microscopic change in liver vascular biology alongside a clinically recognizable metabolic effect. Rather than treating hypertriglyceridemia as an isolated laboratory abnormality, the research suggests that the condition may be linked to changes in the liver’s filtration and exchange environment.
Clozapine’s metabolic effects are complex. The drug influences multiple signaling systems, including pathways involved in appetite, energy balance and glucose regulation. Patients receiving it may experience changes in body composition and lipid metabolism, but these effects do not occur in exactly the same way or to the same degree in everyone. The new findings add another potential layer to that picture by directing attention toward the sinusoidal endothelium, a cell population that is often overlooked in discussions of psychiatric medications.
The association reported in the article does not, by itself, prove that defenestration causes elevated triglycerides, or that clozapine directly damages LSECs. Biological relationships can run in several directions. High circulating lipids might contribute to endothelial remodeling; clozapine might affect both processes through a shared metabolic pathway; or other factors, including weight change, inflammation, insulin resistance and individual susceptibility, might connect them. Establishing causality will require carefully controlled experiments and studies that follow patients over time.
The discovery could nevertheless have practical significance. Triglyceride testing is already part of metabolic monitoring for people taking antipsychotic medicines, particularly clozapine. If future research confirms that LSEC changes precede or predict worsening hypertriglyceridemia, markers of liver endothelial function could eventually complement conventional blood tests. Such tools might help clinicians identify patients at higher risk and consider nutritional counseling, exercise support, medication adjustments or lipid-lowering treatment before complications develop.
The work also highlights why the liver should be studied as an organ of cellular interfaces rather than simply as a chemical processing plant. Its health depends on constant communication among hepatocytes, endothelial cells, immune cells and the extracellular matrix. The fenestrated structure of LSECs is part of that communication network. By connecting clozapine-associated lipid abnormalities with the loss of these microscopic pores, the study opens a new research avenue at the intersection of psychiatry, hepatology and vascular biology. The findings may ultimately help scientists design safer treatment strategies without sacrificing the unique therapeutic benefits that make clozapine indispensable for some patients.
Subject of Research: Association between clozapine-induced hypertriglyceridemia and structural changes in liver sinusoidal endothelial cells.
Article Title: Association between clozapine-induced hypertriglyceridemia and defenestration of liver sinusoidal endothelial cells.
Article References: Voloshyna, T., Svendsen, Ø.V., Szafranska, K. et al. “Association between clozapine-induced hypertriglyceridemia and defenestration of liver sinusoidal endothelial cells.” Translational Psychiatry (2026). https://doi.org/10.1038/s41398-026-04328-4
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41398-026-04328-4
Keywords: clozapine, hypertriglyceridemia, liver sinusoidal endothelial cells, LSECs, defenestration, lipid metabolism, antipsychotic medication, liver biology, metabolic side effects
